Navigation Links
Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
Date:7/1/2009

of the resulting drug product, such as binding potency and structural integrity, are maintained by the In-Line labeling process."

"This new In-Line labeling process is elegant in its simplicity but dramatic in the benefits achieved," said Steven W. King, president and CEO of Peregrine. "The process is extremely versatile and easy to use, and it can produce large quantities of labeled drug product rapidly, reliably and cost-effectively. We have been using the new process to produce Cotara for our ongoing brain cancer trials and can report that it works as well in clinical practice as it does in the lab. We believe it is significant that this innovative process has been granted a European patent and coincidently is featured in a newly released major peer-reviewed publication. We intend to make this exciting technology available for license on a worldwide basis."

The continuous In-Line manufacturing method has European patent protection under European Patent Number 1 638 989. It was developed by inventors at Peregrine and the Paul Scherrer Institute in Switzerland, which has exclusively licensed its rights in the technology to Peregrine Pharmaceuticals.

1. Harris, D., Pellikka, R., Gasser, O., Blaeuenstein, P., Waibel, R., Schubiger, P.A., King, S., Parseghian, M. (2009). In-Line Radiolabeling: A Novel Continuous Flow System for Commercial-Scale Protein Labeling. Journal of Nuclear Medicine 50(7):1178-1186.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Av
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... Dennis R. HIll M.D. Radiation Oncologist at the Alta ... there has been a promotion of the idea that a ... or low dose rate, brachytherapy for prostate cancer. The claim ... shorter half life, and gives a higher biologically effective dose ... a higher average energy than the other commonly used prostate ...
(Date:5/24/2013)... , May 24, 2013 InspireMD, ... in embolic protection stents, announced that Alan Milinazzo ... Craig Shore , the Company,s Chief Financial ... Conference on Thursday May 30, 2013 at The Pfister Hotel, ... The format of the conference includes a number ...
(Date:5/24/2013)... 24, 2013 The Oklahoma tornado ... its ravage, the mayor of Moore, one of the heavily ... said a report from cnn.com. Reaching out to also be ... Molderizer and Safe Shield to counter the looming mold problem. ... on May 22, 2013, caused 24 deaths, My Cleaning Products ...
(Date:5/23/2013)... their baby stopped breathing, his collapsed bronchus blocking the ... Bryan Gionfriddo watched helplessly, just praying that somehow the ... said he had a good chance of not leaving ... 20-month-old son, Kaiba. "At that point, we were desperate. ... run with it." , They found hope at the ...
Breaking Biology Technology:Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 2Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 3InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3
... An engineered metamaterial proved it can function as ... the electromagnetic spectrum, setting a standard of performance for ... of researchers from Boston College, the Los Alamos ... electrical current applied to the metamaterial a hybrid ...
... of MyMedicalRecords Pro to be Showcased For ... at HIMSS09LOS ANGELES, Feb. 24 MMR ... which through its wholly-owned operating subsidiary, MyMedicalRecords, ... Records ("PHRs") ( www.mymedicalrecords.com ) and electronic ...
... The European Commission has granted,marketing authorisation for ... the treatment of adult patients,with major depressive episodes. ... great scope for improved therapies to treat the,devastating ... Oxford, United Kingdom. "Valdoxan is an innovative, new ...
Cached Biology Technology:Team develops new metamaterial device 2Team develops new metamaterial device 3MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 2MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 3MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 4MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 5Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe 2Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe 3
(Date:5/23/2013)... discovering the new mechanism by which estrogen suppresses lipid ... a potential new approach toward treating certain liver diseases. ... colleagues believe they are changing long-held views in the ... of the journal Science Signaling . , "The ... has been that only receptors located in the nucleus ...
(Date:5/23/2013)... surgery or harsh treatments because science fails to ... of the disease. Researchers at Case Western Reserve ... technology that allows patients to safely choose to ... take drastic measures. , The project is one ... biomedical engineering at Case Western Reserve and director ...
(Date:5/23/2013)... history museums of the world are billions of animal ... flowers, mushrooms and grasses, all stacked, stored and preserved ... diverse collections could be critical to understanding how the ... growing human footprint if only the information were ... life with the help of a team from the ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4
... Weizmann Institute scientists has turned the tables on an autoimmune ... immune system mistakenly attacks the body,s tissues. But the scientists ... one of the body,s players in autoimmune processes, an enzyme ... in Nature Medicine . Prof. Irit Sagi of ...
... Friday, December 23, 2011, Cleveland: Cleveland Clinic researchers ... thyroid cancer, which is has the largest incidence increase ... led by Charis Eng, M.D., Ph.D., Chair and founding ... Lerner Research Institute, included nearly 3,000 patients with Cowden ...
... Many imaging technologies and their contrast agents chemicals used ... involve exposure to radiation or heavy metals, which present potential ... be applied. In an effort to mitigate these drawbacks, new ... coat an iron-based contrast agent so that it only interacts ...
Cached Biology News:New synthetic molecules treat autoimmune disease in mice 2Cleveland Clinic researcher discovers genetic cause of thyroid cancer 2Penn engineers develop more effective MRI contrast agent for cancer detection 2Penn engineers develop more effective MRI contrast agent for cancer detection 3
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
... to just 15 minutes! The name Instant ... be drawn between this exciting new laboratory concept ... Instant meals consumed by astronauts, explorers and ... reconstituted by adding water. The Instant ELISA ...
Request Info...
Request Info...
Biology Products: